Zilver PTX Drug-Eluting Peripheral Stent
Cook Ireland, Ltd. · Decision date Mar 25, 2026
What did the FDA decide?
FDA records P100022/S045 as a supplement to PMA P100022, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Mar 25, 2026.
FDA approval order statement
an approval for a change in the annual monitoring stability study sampling plan
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 25, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P100022/S045
- Regulatory pathway
- PMA supplement
- Applicant
- Cook Ireland, Ltd.
- Product code
- NIU
- Decision code
- OK30
- Decision date
- Mar 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, superficial femoral artery, drug-eluting.
- Applicant
- Cook Ireland, Ltd.
- Product code
- NIU
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100022. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100022 · Original PMA
ZILVER PTX DRUG-ELUTING PERIPHERAL STENT
P100022/S045 received
Application receipt date recorded by FDA.
P100022/S045 · FDA decision
30-Day Notice
P100022/S046 · Related supplement
Zilver PTX Drug-Eluting Peripheral Stent
Timeline entries are records held by MedtechLedger for P100022. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100022
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cook Ireland, Ltd. | PMA approval | Nov 14, 2012 | FDA | |
Zilver PTX Drug-Eluting Peripheral StentP100022/S046 | Cook Ireland, Ltd. | PMA supplement | Nov 6, 2026 | FDA |
Explore the linked device profile
Other records with product code NIU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ELUVIA Drug-Eluting Vascular Stent SystemP180011/S070 | Boston Scientific Corp | PMA supplement | Aug 21, 2026 | FDA |
Eluvia Drug-Eluting Vascular Stent SystemP180011/S069 | Boston Scientific Corp | PMA supplement | Aug 6, 2026 | FDA |
Eluvia Drug-Eluting Vascular Stent SystemP180011/S060 | Boston Scientific Corp | PMA supplement | Jan 30, 2026 | FDA |
Eluvia Drug-Eluting Vascular Stent SystemP180011/S067 | Boston Scientific Corp | PMA supplement | Oct 24, 2025 | FDA |
Eluvia Drug-Eluting Vascular Stent SystemP180011/S066 | Boston Scientific Corp | PMA supplement | Aug 8, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cook Ireland, Ltd.
- Headquarters
- Not reported
- Brand website
- cookmedical.com
- FDA applicant address
- O' Halloran Rd., National Technology Park, Limerick
Sources and methodology
- Original FDA record: P100022/S045
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


